Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study

Saemundur Rognvaldsson1,2,9, Elias Eythorsson2,9, Sigrun Thorsteinsdottir1,3, Brynjar Vidarsson2, Pall Tor Onundarson1,2, Bjarni A.agnarsson1,2, Margret Sigurdardottir2, Ingunn Thorsteinsdottir2, Islelfur Olfsson1,2, Hrafnhildur L. Runolfsdottir1,2, Dadi Helgason2, Arna R. Emilsson2, Arnar S. Agustsson1,2, Aron H. Bjornsson1,2, Gudrun Kristjansdottir2, Asdis Rosa Thorardottir1, Olafur Skuli Indridason1,2, Andri Olafsson1,4, Gauti Kjartan Gislason1,2, Gudrun Kristjansdottir2,8, Hlif Steingrimsdottir2, Petros Kampanis5, Malin Hultcrantz6, Brian G. M. Durie7, Stephen Harding5, Ola Landgren8, Runolfur Palsson1,2, Thorvarður Jon Love1,2 and Sigurdur Yngvi Kristinsson7,2,5,6

© The Author(s) 2021

Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM, has been associated with immune dysfunction which may lead to severe COVID-19. No systematic data have been published on COVID-19 in individuals with MGUS. We conducted a large population-based cohort study evaluating the risk of SARS-CoV-2 infection and severe COVID-19 among individuals with MGUS. We included 75,422 Icelanders born before 1976, who had been screened for MGUS in the Iceland Screens Treats or Prevents Multiple Myeloma study (iStopMM). Data on SARS-CoV-2 testing and COVID-19 severity were acquired from the Icelandic COVID-19 Study Group. Using a test-negative study design, we included 32,047 iStopMM participants who had been tested for SARS-CoV-2, of whom 1754 had MGUS. Among these participants, 1100 participants, tested positive, 65 of whom had MGUS. Severe COVID-19 developed in 230 participants, including 16 with MGUS. MGUS was not associated with SARS-CoV-2 infection (Odds ratio (OR): 1.05; 95% confidence interval (CI): 0.98–1.13; p = 0.72) or severe COVID-19 (OR: 0.99; 95%CI: 0.52–1.91; p = 0.99). These findings indicate that MGUS does not affect the susceptibility to SARS-CoV-2 or the severity of COVID-19.

Blood Cancer Journal (2021) 11:191; https://doi.org/10.1038/s41408-021-00580-7

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China in 2019 [1], and has since developed into a global pandemic. The clinical presentation of the associated coronavirus disease 19 (COVID-19) varies from mild disease to multi-organ failure and death [2]. Risk factors for severe COVID-19 have been identified, including age, male sex, and several comorbidities including cancer [3].

Patients with multiple myeloma (MM), a malignancy of bone marrow plasma cells, are at a particularly high risk of developing severe illness when infected by SARS-CoV-2 [4–7]. Potential pathobiological mechanisms have been suggested, including immunosuppressive therapy, inherent suppression and dysregulation of humoral and cellular immunity, and MM-associated kidney disease. Currently, high disease burden, and severe hypogammaglobulinemia have been associated with increased risk for severe COVID-19 in MM patients, whilst treatment-related factors have not [4–7].

The precursor condition of MM, monoclonal gammopathy of undetermined significance (MGUS) [8, 9] is characterized by the presence of monoclonal immunoglobulins (M proteins) or free light chains (FLC) in the serum without MM-defining clinical or biological markers [10]. MGUS is common, affecting 4.2% of the general population over 50 years of age [11, 12]. MGUS has been associated with a similar but milder inherent immune dysfunction as MM, including significant defects in both humoral and cellular immunity [13] and relatively high rates of hypogammaglobulinemia (25%) [11, 14]. Furthermore, MGUS has been associated with a two-fold risk of bacteremia and almost three-fold risk of viral infections [15]. MGUS has also been associated with thrombosis [16] and kidney disease [17], both of which are features of and risk factors for severe COVID-19 [3]. Therefore, it has been speculated that individuals with MGUS might have an increased risk of SARS-CoV-2 infection and severe COVID-19 [18]. In a recently reported small (n = 7) case series of individuals with MGUS who were infected with SARS-CoV-2, five required hospitalization and one died [19]. However, no systematic data on MGUS and COVID-19 have been published to date.

MGUS is usually asymptomatic and is most often diagnosed incidentally during evaluation of unrelated medical problems. This
leads to a biased selection of individuals with other comorbidities that may generate false associations between MGUS and various diseases. In fact, a previous study of a screened MGUS cohort in the US could not confirm many of the disease associations found in clinical cohorts [20], highlighting the need to use screened MGUS cohorts to assess the association of MGUS with other diseases, including COVID-19.

Here, we report the first study of COVID-19 in individuals with MGUS using data from the ongoing Iceland Screens Treats or Prevents Multiple Myeloma study (iStopMM), which has already screened 75,422 Icelanders for MGUS. The objective of the study was to evaluate the risk of SARS-CoV-2 infection and severe COVID-19 in individuals with MGUS. Based on the previous literature we hypothesized that MGUS might increase the risk of SARS-CoV-2 infection and severe COVID-19.

METHODS

Ethical approval

The iStopMM study, data collection for Icelandic patients with SARS-CoV-2 infection, and crosslinking of healthcare data has been approved by the Icelandic National Bioethics Committee (VSN 16-022, date: 2016-04-26; VSN 20-078, date: 2021-05-26) with additional approval from the Icelandic Data Protection Agency. The iStopMM study has been registered on ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT03237597).

COVID-19 in Iceland

The first case of SARS-CoV-2 infection in Iceland was diagnosed on February 28, 2020. The Icelandic authorities implemented an aggressive testing strategy early in the pandemic that included targeted testing based on clinical suspicion, open invitation population screening, and random screening for SARS-CoV-2 among asymptomatic persons [21]. As the pandemic continued, random screening was discontinued, while self-ordered testing with same-day results became available to all and double screening of individuals in quarantine and persons arriving at the border was initiated. All SARS-CoV-2 testing was done by real-time quantitative polymerase chain reaction (qPCR) of simultaneously acquired oropharyngeal and nasopharyngeal swabs. Through this approach, Iceland has polymerase chain reaction (qPCR) of simultaneously acquired oropharyngeal and nasopharyngeal swabs. Through this approach, Iceland has managed to keep case numbers low and has been able to test everyone in the population. In total, 6,126 individuals were found to be SARS-CoV-2-positive.

During the COVID-19 pandemic, random screening was discontinued, while self-ordered testing with same-day results became available to all and double screening of individuals in quarantine and persons arriving at the border was initiated. All SARS-CoV-2 testing was done by real-time quantitative polymerase chain reaction (qPCR) of simultaneously acquired oropharyngeal and nasopharyngeal swabs. Through this approach, Iceland has managed to keep case numbers low and has been able to test everyone in the population. In total, 6,126 individuals were found to be SARS-CoV-2-positive.

RESULTS

Of the 75,422 participants who had been screened for MGUS, 1,854 had died and 693 had been diagnosed with MM and related disorders before the study period. A total of 32,047 participants, of whom 1,754 (5.5%) had MGUS, had been tested for SARS-CoV-2 (Fig. 1). Those who had MGUS were older (mean age 66.3 vs 59.1 years, \( p < 0.001 \)) and more likely to be male (50% vs 41%, \( p < 0.001 \)) than those who did not have MGUS. Of those tested, 1,100 (3.4%) were positive for SARS-CoV-2, including 65 who had MGUS. After adjusting for sex and age, MGUS was not found to be associated with SARS-CoV-2 infection (odds ratio (OR): 1.05; 95% confidence interval (CI): 0.81–1.36; \( p = 0.72 \)). The findings were similar for HC- and LC-MGUS (Table 1 and Fig. 2). Sensitivity analysis that included the whole study cohort showed essentially the same results (Supplemental Table). There was no significant association between MGUS and the rate of SARS-CoV-2 testing (Supplemental Table).

DISCUSSION

This large nationwide cohort study is the first population-based study evaluating COVID-19 susceptibility and severity among individuals with MGUS and severe COVID-19. Participants from the previous analysis who tested positive for SARS-CoV-2 were included. Those who were hospitalized for other medical problems or were living in a nursing home at the time of testing were excluded. Participants were followed until discharge from telehealth monitoring or until they had developed severe COVID-19. Severe COVID-19 was defined as the composite outcome of requiring an emergency outpatient visit, requiring hospital admission, or death (emergency outpatient visit or worse). Additionally, we conducted an analysis where severe COVID-19 was defined as hospital admission or death (hospital admission or worse). The association of MGUS with severe COVID-19 was assessed using logistic regression, adjusting for sex and age. Two sensitivity analyses were performed. In the first sensitivity analysis, we evaluated the association of MGUS and SARS-CoV-2 testing in the whole study cohort using logistic regression, adjusting for sex and age. In the second sensitivity analysis, we repeated the first analysis and included the entire study cohort regardless of whether the participants had been tested for SARS-CoV-2 or not.

All analyses were carried out in R, version 3.6.3, using the rms package [25]. The code used for this study and its output have been published online at https://osf.io/kf9g9/.

Study design and statistical analysis

The primary exposure was MGUS as determined by M protein detectable on CZE and confirmed by IFE or an abnormal FLC ratio (kappa/lambda ratio <0.26 and lambda >26.3 g/L or a kappa/lambda ratio >1.65 and kappa >194 g/L). Those with MGUS were further subdivided into heavy chain-MGUS (HC-MGUS) and light-chain MGUS (LC-MGUS) subgroups. All analyses were carried out separately for MGUS, HC-MGUS, and LC-MGUS. When included as a covariate, age was modeled with a four-knot restricted cubic spline.

In the first analysis, we evaluated whether there was an association between MGUS and testing positive for SARS-CoV-2 using a test-negative study design. Participants from the study cohort who had been tested at least once for SARS-CoV-2 between February 28 and December 31, 2020, were included. Those who had at least one positive qPCR test for SARS-CoV-2 were considered to be infected. The association of MGUS and SARS-CoV-2 infection was evaluated using logistic regression adjusting for sex and age.

In the second analysis, we evaluated the association between MGUS and severe COVID-19. Participants from the previous analysis who tested positive for SARS-CoV-2 were included. Those who were hospitalized for other medical problems or were living in a nursing home at the time of testing were excluded. Participants were followed until discharge from telehealth monitoring or until they had developed severe COVID-19. Severe COVID-19 was defined as the composite outcome of requiring an emergency outpatient visit, requiring hospital admission, or death (emergency outpatient visit or worse). Additionally, we conducted an analysis where severe COVID-19 was defined as hospital admission or death (hospital admission or worse). The association of MGUS with severe COVID-19 was assessed using logistic regression, adjusting for sex and age. Two sensitivity analyses were performed. In the first sensitivity analysis, we evaluated the association of MGUS and SARS-CoV-2 testing in the whole study cohort using logistic regression, adjusting for sex and age. In the second sensitivity analysis, we repeated the first analysis and included the entire study cohort regardless of whether the participants had been tested for SARS-CoV-2 or not.

All analyses were carried out in R, version 3.6.3, using the rms package [25]. The code used for this study and its output have been published online at https://osf.io/kf9g9/.

Study cohort

The study cohort was comprised of participants in the iStopMM study who had been screened for MGUS before December 31, 2020 and were alive and had not been diagnosed with MM and related disorders, including smoldering MM requiring treatment, before February 28, 2020. iStopMM is a population-based screening study for MGUS and randomized trial of follow-up strategies in Iceland. All Icelanders born in 1975 (n = 148,704) and earlier were invited to participate and 80,759 (54%) accepted and provided informed consent between September 2016 and February 2018. Serum samples were collected from 75,422 study participants (93%) between September 9, 2016 and December 31 2020 and screened for MGUS by capillary zone electrophoresis (CZE), immunofixation electrophoresis (IFE), and serum FLC assay. The iStopMM study design has previously been described in detail [24].
persons with MGUS. Although previous authors have speculated that MGUS may impact the risk of SARS-CoV-2 infection and especially the risk of severe COVID-19 [18], we did not find MGUS to be associated with contracting SARS-CoV-2 or developing severe COVID-19 once infected.

MGUS was not associated with an increased risk of SARS-CoV-2 infection. This contradicts previous studies that have found individuals with MGUS to have an increased risk of infections, including viral infections [15]. This might indicate that this increased risk of viral infections does not apply to COVID-19.

---

**Table 1.** Baseline characteristics of study participants tested for SARS-CoV-2 and the association between MGUS and SARS-CoV-2 infection.

|                  | No MGUS | MGUS   | HC-MGUS | LC-MGUS |
|------------------|---------|--------|---------|---------|
| n                | 30,293  | 1754   | 1140    | 614     |
| Mean age (SD)    | 59 (10) | 66 (11) | 65.9 (11) | 66.9 (11) |
| Men              | 12,283 (41%) | 880 (50%) | 571 (50%) | 309 (50%) |
| Person-years     | 24,882  | 1431   | –       | –       |
| SARS-CoV-2-positive | 1035 (3.4%) | 65 (3.7%) | 41 (3.6%) | 24 (3.9%) |
| OR of SARS-CoV-2 positivity (95% CI)* | Ref | 1.05 (0.80-1.36) | 1.02 (0.74-1.40) | 1.11 (0.73-1.69) |

MGUS monoclonal gammopathy of undetermined significance, HC-MGUS heavy chain MGUS, LC-MGUS light chain MGUS, SD standard deviation, COVID-19 coronavirus disease 2019, OR odds ratio, CI confidence interval, Ref reference.

* Adjusted for age and sex.
However, these studies were based on individuals with incidentally diagnosed MGUS, which may have biased the sample to include individuals with more comorbid conditions. By contrast, our study is based on a cohort of persons who were screened for MGUS and underwent a high rate of SARS-CoV-2 testing (42% being tested at least once) and no difference in the frequency of testing between those with and without MGUS. This minimizes the possibility of detection bias due to MGUS in this study.

Individuals with MGUS did not have an increased risk of severe COVID-19 compared to those without MGUS. This is in contrast to MM, which has been associated with severe COVID-19 [4–7]. Severe COVID-19 is believed to be caused by immune dysregulation and hyperactivation [26]. Disease factors rather than treatment factors in MM have been associated with severe COVID-19 [4–7]. It is therefore unexpected that we did not find an increased risk of severe COVID-19 in individuals with MGUS, who have been shown to have similar, although milder, dysregulation of humoral and cellular immune function [13]. These findings indicate that more severe immune dysregulation, as seen in MM, contributes to the risk of severe COVID-19 or that the effects of treatment factors have been underestimated in previous studies.

This study has several strengths. Firstly, the entire study population was screened for MGUS, thereby eliminating the selection bias present in most other MGUS cohorts where disorder is primarily diagnosed in those who have other medical problems and are therefore likely to have a greater burden of comorbid conditions. Furthermore, the non-MGUS group had been tested for MGUS removing potential false negatives from that study group. Secondly, the comprehensive and aggressive SARS-CoV-2 testing strategy employed in Iceland has yielded a high case capture rate compared to other nations. Thirdly, data on diagnosis and follow-up of COVID-19 cases, which has been collected by the same clinical team, are virtually complete, and centrally registered for the whole nation. Finally, the study included a large number of persons who represent a significant proportion of the nation’s population.

### Table 2. Baseline characteristics of SARS-CoV-2-positive participants and the association between MGUS and severity of COVID-19.

|                  | No MGUS | MGUS | HC-MGUS | LC-MGUS |
|------------------|---------|------|---------|---------|
| **n**            | 1004    | 56   | 35      | 21      |
| Mean age (SD)    | 59 (10) | 65 (11) | 65 (12) | 65 (10) |
| Men              | 448 (45%) | 30 (54%) | 22 (63%) | 8 (38%) |
| Person-days      | 16,589 | 962  | –       | –       |
| Emergency outpatient visit | 176 (18%) | 12 (20%) | 7 (20%) | 5 (24%) |
| Hospital admission | 105 (11%) | 11 (20%) | 8 (23%) | 3 (14%) |
| Intensive care unit admission | 20 (2%) | 3 (5%) | 2 (6%) | 1 (5%) |
| Death            | 5 (1%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Emergency outpatient visit or worse | 214 (21%) | 16 (29%) | 10 (29%) | 6 (29%) |
| OR (95% CI)*     | Ref     | 0.99 (0.52–1.91) | 0.90 (0.39–2.08) | 1.10 (0.39–3.10) |
| Hospital admission or worse | 106 (11%) | 11 (20%) | 8 (23%) | 3 (14%) |
| OR (95% CI)*     | Ref     | 1.13 (0.52–2.46) | 1.25 (0.49–3.19) | 0.83 (0.21–3.29) |

MGUS monoclonal gammopathy of undetermined significance, HC-MGUS heavy chain MGUS, LC-MGUS light chain MGUS, SD standard deviation, COVID-19 Coronavirus disease 2019, OR odds ratio, CI confidence interval, Ref reference.

* Adjusted for age and sex.
population making the findings likely to be generalizable to similar populations. This study also has limitations. Firstly, we included individuals based on blood testing alone which does not completely exclude more advanced diseases than MGUS. However, those who had MM or related disease, including smoldering MM in treatment, were excluded. Secondly, despite being the largest study to date with more than 75,422 participants, the number of events was relatively low, and therefore, the study might be underpowered to detect a modest increase in risk. Thirdly, due to the relative scarcity of participants with MGUS and SARS-CoV-2 infection and the low mortality from COVID-19 in Iceland, hard endpoints were too rare for this analysis requiring the use of composite outcomes. Finally, the Icelandic population is highly genetically homogenous and mostly white, limiting generalization in non-white populations.

In conclusion, in this large population-based cohort study including 75,422 individuals screened for MGUS, we did not find MGUS to be a risk factor for contracting SARS-CoV-2 or developing severe COVID-19. These findings are important since MGUS is the most common precursor condition of hematological malignancy, affecting millions of individuals worldwide [11, 12]. The findings provide guidance for how physicians should counsel their patients with MGUS about their risks during the COVID-19 pandemic.

REFERENCES
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.
2. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl J Med. 2020;382:1708–20. https://doi.org/10.1056/nejmoa2002122.
3. Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T, et al. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest. 2020;158:97–105. https://doi.org/10.1016/j.chest.2020.04.010.
4. Hultcrantz M, Richter J, Rosenbaum CA, Patel D, Smith EL, Korde N, et al. COVID-19 infections and critical outcomes in patients with multiple myeloma in New York City: A Cohort Study from Five Academic Centers. Blood Cancer Discov. 2020;1:234–43. https://doi.org/10.1158/2643-3230.bcd-20-0102.
5. Wang B, Van Oekelen O, Mouhieddine TH, Del Valle DM, Richter J, Cho HJ et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol. 2020;13. https://doi.org/10.1186/s1470-2045(20)10034-x.
6. Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136:3303–40. https://doi.org/10.1182/blood.2020008150.
7. Martinez-Lopez J, Mateos M-V, Encinas C, Sureda A, Hernandez-Rivas JA, Lopez De La Guia, A et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inapartent mortality. Blood Cancer J. 2020;10: https://doi.org/10.1038/s41408-020-00372-5.
8. Langdren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammapathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412–5417. https://doi.org/10.1182/blood-2008-12-194241.
9. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammapathy precedes multiple myeloma in most patients. Blood. 2009;113:5418–22. https://doi.org/10.1182/blood-2008-12-195008.
10. Rajkumar SV, Dimopoulos MA, Palumbo A, Blay J, Merlini G, Mateos M-V et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. J Hematol Oncol. 2014;7:58–e548. https://doi.org/10.1182/jhmo.2014-000449.
11. Gregory P, Manden KM, Sorensen HT, Schanheyder HC, Ibsen JS, Dahleuf JP. The risk of bacteremia in patients with monoclonal gammapathy of undetermined significance. Eur J Haematol. 2009;84:140–144. https://doi.org/10.1111/j.1600-0609.1998.tb01075.x.
12. Kristinsson SS, Tang M, Pfeiffer RM, Bjorkholm M, Goldin LR, B limark C, et al. Monoclonal gammapathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97:854–858. https://doi.org/10.3324/haematol.2011.054015.
13. Jain A, Ramasamy K. Potential ‘significance’ of monoclonal gammapathy of undetermined significance during COVID-19 pandemic. Blood Cells Mol Dis. 2020;85:102481–102481. https://doi.org/10.1016/j.bcmd.2020.102481.
14. Gonzalez-Lugo JD, Bacher-Rodriguez L, Goldfinger M, Shastri A, Sica RA, Gritsman K et al. A case series of monoclonal gammapathy of undetermined significance and COVID-19. Br J Haematol. 2020; https://doi.org/10.1111/bjh.16906.
15. Bida JP, Kyle RA, Therneau TM, Melton LJ, Plevak MF, Larson DR, et al. Disease associations with monoclonal gammapathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc. 2009;84:685–93. https://doi.org/10.4065/84.8.685.
16. Gudbjartsen DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic Population. N. Engl J Med. 2020;382:2302–15. https://doi.org/10.1056/nejmoa2006100.
17. Icelandic Directorate of Health. COVID-19 in Iceland - Statistics, https://www.covid.is/data.
18. Helgason D, Eythorsson E, Olafsdottir LB, Agustsson T, Ingvarsdottir S, Sverrisdottir S et al. Beating the odds with systemic individualized care: nationwide prospective follow-up of all patients with COVID-19 in Iceland. J Internal Med. 2020. https://doi.org/10.1111/jim.13135.
19. Rognvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Óskarsson JÞ, Pétursdóttir Í, et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammapathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021;11:94. https://doi.org/10.1038/s41408-021-00480-w.
20. Harrell FE Jr Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. Springer; 2015.
21. Yao C, Bora SA, Parimon T, Zaman T, Friedman OA, Palatinus JA et al. Cell-type-specific immune dysfunction in severely ill COVID-19 patients. Cell Rep. 2021;34, https://doi.org/10.1016/j.celrep.2020.108590.

ACKNOWLEDGEMENTS
The iStopMM study is funded by the Black Swan Research Initiative by the International Myeloma Foundation, the European Research Council, and the Icelandic Center for Research. Screening tests were performed by The Binding Site Ltd, Birmingham, UK. Additional funding for the iStopMM study is provided by the University of Iceland, Landsdálag—The National University Hospital of Iceland, and the Icelandic Cancer Society. The iStopMM study is made possible the nurses, data scientists, and other staff of the study as well as by the hundreds of nurses and laboratory technicians who had collected blood samples for the study. Most importantly, our gratitude goes to the thousands of Icelanders who have generously provided their informed consent for the study, answered questionnaires, provided blood samples, and undergone diagnostic testing and follow-up.

AUTHOR CONTRIBUTIONS
S.R. and S.Y.K. wrote the manuscript with input from E.E. and R.P. The study was designed by S.R. and E.E. under the supervision of S.Y.K. and R.P. E.E. acquired and crosslinked data and performed statistical analysis. S.R., E.E., S.T., B.V., P.T.O., B.A.A., M.S., I.T., I.O., A.J., P.K., A.R.T., G.K., G.K.G., A.O., H.S., M.H., B.G.M.D., O.L., T.J.L., R.P., O.S.I., S.H. and S.Y.K. contributed significantly to the design and implementation of the iStopMM study. E.E., H.L.R., D.H., A.R.E., A.S.A., A.H.B., O.S.I. and R.P. contributed significantly to the collection of data on COVID-19 that was curated by E.E. All authors reviewed and edited the manuscript and approved the final manuscript. S.R. and E.E. had an equal contribution to the study and are both considered first authors of the paper.
COMPETING INTERESTS
P.K. is an employee of The Binding Site. M.H. has received research funding from Amgen and Daiichi Sankyo, has provided consultancy for Intellisphere LLC and Curio Science LLC, and served on an advisory committee for GlaxoSmithKline. B.G.M.D. has provided consultancy for Amgen, Janssen, Celgene, Takeda. S.H. is the director of The Binding Site. O.L. has received research funding from National Institutes of Health (NIH), National Cancer Institute (NCI), U.S. Food and Drug Administration (FDA), Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), Leukemia and Lymphoma Society (LLS), Perelman Family Foundation, Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; and received honoraria/compensation for advisory boards from Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees (IDMCs) for clinical trials lead by Takeda, Merck, Janssen, Theradex. S.Y.K. has received research funding from International Myeloma Foundation, European Research Council, Icelandic Center for Research (Rannís), Amgen, Celgene. Other coauthors have nothing to disclose.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41408-021-00580-7.

Correspondence and requests for materials should be addressed to Sigurdur Yngvi Kristinsson.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021